Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
doi: 10.3389/fonc.2026.1878450 Received 11 May 2026 Revised 09 July 2026 Accepted 23 July 2026 Published 31 July 2026 Volume 16 - 2026 Edited by Matteo Becatti, University of Firenze, Italy Reviewed by Sutapa Mukherjee, Chittaranjan National Cancer Institute (CNCI), India Yong Zhi Lun, Putian University, China Updates Copyright 2026 Lee, Yeo, Kim, Lee, Singh, Kim, Oh and Park
2021 Mar 13;10(6):1202
GLP-1R is abundantly present in the pancreatic beta cells, gut, and the CNS, including the cerebral cortex, hippocampus, hypothalamus, thalamus, caudate-putamen and globus pallidum (89, 106108)
As oral GLP1 drugs make their debut alongside established injectables, the conversation around obesity and type 2 diabetes is rapidly evolving
Evidence of increased RGC in patients receiving GLP-1RAs has been demonstrated both by endoscopy [68] and gastric ultrasound [911]
Lancet Diabetes Endocrinol 4(3):221232
